HealthMore in Health→
Roche and C4 Therapeutics Deepen Their Bet on DACs
Key Takeaways
- Roche is expanding work with C4 Therapeutics in a DAC-focused deal worth $20 million upfront.
- Endpoints says DACs are gaining traction as a degrader-based variation on antibody-drug conjugates.
- The agreement extends a partnership between the two companies that has lasted about a decade.
DE
DT Editorial Team··via endpoints.news